PAR 29.3% 26.5¢ paradigm biopharmaceuticals limited..

research reports and media, page-4389

  1. 2,963 Posts.
    lightbulb Created with Sketch. 755
    @Babbanap That is a good point but my concern is the risk the TGA won't see that point of view.
    Hopefully PAR has provided strong evidence as to the urgency of the need for our game-changing drug.

    Also the time frame for the best possible outcome with the TGA is still too far off for our current funding concerns.

 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.